Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Neurophysiological Biomarkers of Parkinson's Disease.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- المصدر:
Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101567362 Publication Model: Print Cited Medium: Internet ISSN: 1877-718X (Electronic) Linking ISSN: 18777171 NLM ISO Abbreviation: J Parkinsons Dis Subsets: MEDLINE
- بيانات النشر:
Original Publication: Amsterdam : IOS Press
- الموضوع:
- نبذة مختصرة :
Background: There is a need for reliable and robust Parkinson's disease biomarkers that reflect severity and are sensitive to disease modifying investigational therapeutics.
Objective: To demonstrate the utility of EEG as a reliable, quantitative biomarker with potential as a pharmacodynamic endpoint for use in clinical assessments of neuroprotective therapeutics for Parkison's disease.
Methods: A multi modal study was performed including aquisition of resting state EEG data and dopamine transporter PET imaging from Parkinson's disease patients off medication and compared against age-matched controls.
Results: Qualitative and test/retest analysis of the EEG data demonstrated the reliability of the methods. Source localization using low resolution brain electromagnetic tomography identified significant differences in Parkinson's patients versus control subjects in the anterior cingulate and temporal lobe, areas with established association to Parkinson's disease pathology. Changes in cortico-cortical and cortico-thalamic coupling were observed as excessive EEG beta coherence in Parkinson's disease patients, and correlated with UPDRS scores and dopamine transporter activity, supporting the potential for cortical EEG coherence to serve as a reliable measure of disease severity. Using machine learning approaches, an EEG discriminant function analysis classifier was identified that parallels the loss of dopamine synapses as measured by dopamine transporter PET.
Conclusion: Our results support the utility of EEG in characterizing alterations in neurophysiological oscillatory activity associated with Parkinson's disease and highlight potential as a reliable method for monitoring disease progression and as a pharmacodynamic endpoint for Parkinson's disease modification therapy.
- References:
Neurology. 2014 Jul 29;83(5):406-12. (PMID: 24975862)
Clin Neurophysiol. 2011 Dec;122(12):2355-64. (PMID: 21924950)
Aviat Space Environ Med. 2007 May;78(5 Suppl):B231-44. (PMID: 17547324)
J Cereb Blood Flow Metab. 1996 Sep;16(5):834-40. (PMID: 8784228)
Clin Neurophysiol. 2013 Oct;124(10):1970-4. (PMID: 23746496)
Brain. 2005 Jun;128(Pt 6):1277-91. (PMID: 15774503)
J Neurol. 2000 Sep;247 Suppl 4:IV/2-7. (PMID: 11199811)
J Clin Neurophysiol. 1998 May;15(3):243-50. (PMID: 9681562)
Brain Imaging Behav. 2015 Dec;9(4):821-7. (PMID: 25511521)
J Parkinsons Dis. 2013;3(1):69-76. (PMID: 23938313)
BMC Neurol. 2002 Sep 12;2:9. (PMID: 12227833)
Brain. 2015 Jun;138(Pt 6):1454-76. (PMID: 25888551)
J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9. (PMID: 17519979)
J Neurol Neurosurg Psychiatry. 2006 Oct;77(10):1136-42. (PMID: 16801351)
Parkinsonism Relat Disord. 2016 Jan;22:54-61. (PMID: 26627939)
Neuroimage. 2008 Jan 15;39(2):555-65. (PMID: 17962043)
Mov Disord. 2016 Jul;31(7):1012-9. (PMID: 27062301)
Mov Disord. 2013 Mar;28(3):311-8. (PMID: 23436720)
Parkinsonism Relat Disord. 2014 Apr;20(4):415-20. (PMID: 24467818)
Neuroimage. 1999 Jan;9(1):108-16. (PMID: 9918732)
Mov Disord. 2008 Aug 15;23(11):1608-12. (PMID: 18649394)
J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):36-42. (PMID: 16820421)
Brain. 2003 Sep;126(Pt 9):2081-92. (PMID: 12876143)
J Parkinsons Dis. 2017;7(3):491-501. (PMID: 28671143)
Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1220-30. (PMID: 12811422)
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4. (PMID: 1564476)
Brain. 2015 Jun;138(Pt 6):1642-57. (PMID: 25732184)
Mov Disord. 2014 Mar;29(3):360-7. (PMID: 24038502)
Acta Neuropathol Commun. 2019 Dec 23;7(1):219. (PMID: 31870437)
J Neurosci. 2007 Jan 3;27(1):124-31. (PMID: 17202479)
Ann Neurol. 2015 Feb;77(2):269-80. (PMID: 25448687)
Neuropsychopharmacology. 2013 Oct;38(11):2170-8. (PMID: 23660705)
Mov Disord. 2004 Sep;19(9):1020-8. (PMID: 15372591)
- Grant Information:
R44 AG050326 United States AG NIA NIH HHS; R44 AG054256 United States AG NIA NIH HHS
- Contributed Indexing:
Keywords: Biomarkers; EEG; Parkinson’s disease; dopamine transporter PET; neurophysiology
- الرقم المعرف:
0 (Biomarkers)
0 (Dopamine Plasma Membrane Transport Proteins)
- الموضوع:
Date Created: 20200303 Date Completed: 20210726 Latest Revision: 20230202
- الموضوع:
20230202
- الرقم المعرف:
PMC7242849
- الرقم المعرف:
10.3233/JPD-191844
- الرقم المعرف:
32116262
No Comments.